Lundbeck and Takeda modify the collaboration agreement for Trintellix in the U.S

In accordance with Lundbeck’s Focused Innovator strategy, the collaboration with Takeda for the U.S. entered in September 2007, has evolved to solely a royalty-based model for Lundbeck.

H. Lundbeck A/S (Lundbeck) today announced that in support of Lundbeck’s Focused Innovator strategy with the aim to create financial flexibility and reallocate resources to other growth opportunities, it has been agreed with Takeda Pharmaceutical Company Limited (Takeda) to modify the current collaboration in the U.S. from a co-promotion, cost-sharing, revenue-sharing, and royalty setup to a royalty-based only model effective 1 January 2025.

Consequently, effective from 1 January 2025, Lundbeck will cease all promotional efforts for Trintellix (vortioxetine) in the U.S. This will enable Lundbeck to fully reallocate resources to other growth opportunities, including Rexulti in the U.S. and thereby further accelerate growth for these products.

As part of the agreement, Lundbeck will receive a fixed, undisclosed royalty rate based on net sales in the U.S. for 2025 and 2026. This agreement does not impact any other geographies where Trintellix is marketed.

The agreement is expected to have only a limited impact on revenue and adjusted EBITDA and will therefore not change the financial guidance for 2024 nor is it expected to change Lundbeck’s mid-term targets as communicated in February 2023.